{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:28:05Z","timestamp":1785860885563,"version":"3.56.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1097\/01.ftd.0000211804.89440.74","type":"journal-article","created":{"date-parts":[[2006,6,14]],"date-time":"2006-06-14T04:36:49Z","timestamp":1150259809000},"page":"312-320","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Bioavailability of the Microemulsion Formulation of Cyclosporine (Neoral) With a Generic Dispersion Formulation (Cicloral) in Young Healthy Male Volunteers"],"prefix":"10.1097","volume":"28","author":[{"given":"Frieder","family":"Kees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Gschaidmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Faerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210129","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.trre.2004.01.002","article-title":"Chronic cyclosporine nephrotoxicity in renal transplantation","volume":"18","author":"Bakker","year":"2004","journal-title":"Transplant Rev"},{"key":"R2-8-20210129","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00003495-200262060-00003","article-title":"Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy","volume":"62","author":"Drosos","year":"2002","journal-title":"Drugs"},{"issue":"67","key":"R3-8-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.0366-077X.2004.05949.x","article-title":"Ciclosporin in psoriasis clinical practice: an international consensus statement","volume":"150","author":"Griffiths","year":"2004","journal-title":"Br J Dermatol"},{"issue":"67","key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0366-077X.2004.05950.x","article-title":"The use of ciclosporin in psoriasis: a clinical review","volume":"150","author":"Ho","year":"2004","journal-title":"Br J Dermatol"},{"key":"R5-8-20210129","first-page":"288","article-title":"The FDA guidelines for the treatment of psoriasis using cyclosporine A: are they adequate?","volume":"70","author":"Zackheim","year":"2002","journal-title":"Cutis"},{"key":"R6-8-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00128071-200102010-00007","article-title":"Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients","volume":"2","author":"Faerber","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1018923912135","article-title":"Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation","volume":"11","author":"Mueller","year":"1994","journal-title":"Pharm Res"},{"key":"R8-8-20210129","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","article-title":"Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders","volume":"45","author":"Faulds","year":"1993","journal-title":"Drugs"},{"key":"R9-8-20210129","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2165\/00003495-199550050-00009","article-title":"Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral)","volume":"50","author":"Noble","year":"1995","journal-title":"Drugs"},{"key":"R10-8-20210129","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1016\/j.transproceed.2004.10.018","article-title":"Cicloral versus Neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of Cicloral","volume":"36","author":"Kees","year":"2004","journal-title":"Transplant Proc"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0009-9120(91)90126-Y","article-title":"The clinical significance of cyclosporine metabolites","volume":"24","author":"Yatscoff","year":"1991","journal-title":"Clin Biochem"},{"key":"R12-8-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/dmd.30.6.658","article-title":"Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats","volume":"30","author":"Koehler","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1592\/phco.19.9.753.31536","article-title":"A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers","volume":"19","author":"Min","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1067\/mcp.2000.104642","article-title":"Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe","volume":"67","author":"Villeneuve","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0928-0987(00)00139-1","article-title":"Can oral midazolam predict oral cyclosporine disposition?","volume":"12","author":"Paine","year":"2000","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2362.33.s2.2.x","article-title":"The effects of fruit juices on drug disposition: a new model for drug interactions","volume":"33","author":"Dresser","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1034\/j.1399-0012.2002.02011.x","article-title":"Administration diluents differentiate Neoral from a generic cyclosporine oral solution","volume":"16","author":"Kovarik","year":"2002","journal-title":"Clin Transplant"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-4347(97)00225-9","article-title":"Modified high-performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping","volume":"696","author":"Hoskins","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R19-8-20210129","first-page":"1","article-title":"Sample size determination for bioequivalence assessment by means of confidence intervals","volume":"29","author":"Diletti","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"R20-8-20210129","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0041-1345(03)00516-5","article-title":"Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations","volume":"35","author":"Durlik","year":"2003","journal-title":"Transplant Proc"},{"key":"R21-8-20210129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00007890-200407271-00726","article-title":"Assessment of the bioequivalence of Cysporin, a generic cyclosporin A, by a randomized controlled trial in renal transplant recipients","volume":"78","author":"Hibberd","year":"2004","journal-title":"Transplantation"},{"key":"R22-8-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00007691-200006000-00017","article-title":"Recommendations for bioequivalence testing of cyclosporine generics revisited","volume":"22","author":"Christians","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R23-8-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1432-2277.2005.00078.x","article-title":"Generic cyclosporine formulations: more open questions than answers","volume":"18","author":"Cattaneo","year":"2005","journal-title":"Transpl Int"},{"key":"R24-8-20210129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","article-title":"Cyclosporin clinical pharmacokinetics","volume":"24","author":"Fahr","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"R25-8-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2125.2005.02200.x","article-title":"Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients","volume":"59","author":"Bourgoin","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R26-8-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00007691-200402000-00006","article-title":"Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator","volume":"26","author":"Rousseau","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R27-8-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0009-9120(95)00037-3","article-title":"Alternative cyclosporine metabolic pathways and toxicity","volume":"28","author":"Christians","year":"1995","journal-title":"Clin Biochem"},{"key":"R28-8-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14622416.6.1.37","article-title":"Cytochrome P450 3A polymorphisms and immunosuppressive drugs","volume":"6","author":"Thervet","year":"2005","journal-title":"Pharmacogenomics"},{"key":"R29-8-20210129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.transproceed.2005.01.077","article-title":"Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus","volume":"37","author":"Zhao","year":"2005","journal-title":"Transplant Proc"},{"key":"R30-8-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/bdd.2510150107","article-title":"Dose dependent absorption and linear disposition of cyclosporin A in rat","volume":"15","author":"Lindberg-Freijs","year":"1994","journal-title":"Biopharm Drug Dispos"},{"key":"R31-8-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","article-title":"The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein","volume":"40","author":"Zhang","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R32-8-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/004982599238777","article-title":"Species differences in the hepatic and intestinal metabolism of cyclosporine","volume":"29","author":"Whalen","year":"1999","journal-title":"Xenobiotica"},{"key":"R33-8-20210129","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00007691-199410000-00014","article-title":"Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation","volume":"16","author":"Kovarik","year":"1994","journal-title":"Ther Drug Monit"},{"key":"R34-8-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200008000-00020","article-title":"Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening","volume":"22","author":"Wieling","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R35-8-20210129","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/trre.2001.25653","article-title":"Recent advances in therapeutic monitoring of cyclosporine: absorption profiling","volume":"15","author":"Belitsky","year":"2001","journal-title":"Transplant Rev"},{"key":"R36-8-20210129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1034\/j.1600-6143.2002.20609.x","article-title":"Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve","volume":"2","author":"David-Neto","year":"2002","journal-title":"Am J Transplant"},{"key":"R37-8-20210129","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00007691-200202000-00008","article-title":"Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?","volume":"24","author":"Oellerich","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R38-8-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/lt.20056","article-title":"Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients","volume":"10","author":"Langers","year":"2004","journal-title":"Liver Transpl"},{"key":"R39-8-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00007691-200404000-00025","article-title":"Analytic aspects of cyclosporine monitoring, on behalf of the IFCC\/IATDMCT Joint Working Group","volume":"26","author":"Morris","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R40-8-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/clinchem\/45.3.371","article-title":"Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific?","volume":"45","author":"Steimer","year":"1999","journal-title":"Clin Chem"},{"key":"R41-8-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00007691-200404000-00023","article-title":"Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry","volume":"26","author":"Taylor","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"1","key":"R42-8-20210129","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.1111\/j.1365-2125.2001.00365.x","article-title":"Immunosuppressant drugs\u2014the role of therapeutic drug monitoring","volume":"52","author":"Johnston","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R43-8-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00007691-200406000-00003","article-title":"Monitoring immunosuppressive drugs: has it a future?","volume":"26","author":"Holt","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R44-8-20210129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-004-0774-8","article-title":"Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients","volume":"60","author":"Johnston","year":"2004","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.ftd.0000211804.89440.74","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:34:32Z","timestamp":1785857672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200606000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ftd.0000211804.89440.74","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}